Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 114691-92-8 | MDL No. : | MFCD00230828 |
Formula : | C15H12O3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | PDBQNVDCQVGALU-UHFFFAOYSA-N |
M.W : | 240.25 g/mol | Pubchem ID : | 4199915 |
Synonyms : |
|
Num. heavy atoms : | 18 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.07 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 69.03 |
TPSA : | 54.37 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.47 cm/s |
Log Po/w (iLOGP) : | 1.96 |
Log Po/w (XLOGP3) : | 3.24 |
Log Po/w (WLOGP) : | 3.25 |
Log Po/w (MLOGP) : | 2.71 |
Log Po/w (SILICOS-IT) : | 3.29 |
Consensus Log Po/w : | 2.89 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -3.67 |
Solubility : | 0.0518 mg/ml ; 0.000216 mol/l |
Class : | Soluble |
Log S (Ali) : | -4.06 |
Solubility : | 0.0212 mg/ml ; 0.0000881 mol/l |
Class : | Moderately soluble |
Log S (SILICOS-IT) : | -4.63 |
Solubility : | 0.00562 mg/ml ; 0.0000234 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.5 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P233-P260-P261-P264-P270-P271-P280-P301+P312-P302+P352-P304-P304+P340-P305+P351+P338-P312-P321-P330-P332+P313-P337+P313-P340-P362-P403-P403+P233-P405-P501 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With C11H16NPol; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 16h; | 1- (Cyclobutyl)-hexahydro-1 H-1, 4-diazepine dihydrochloride (D4) (0.15g) was stirred with diethylaminomethyl polystyrene (1. 0g), HOBT (0.045g) and 4'-acetyl-4- biphenylcarboxylic acid (0. 13g) in DCM (5ml). EDC (0. 16g) was then added and the reaction stirred at rt for 16h. The polymer supported base was filtered off and the filtrate was diluted with DCM (10mut) and washed with saturated sodium hydrogen carbonate (2 x 15ml). The organic layer was loaded directly onto a silica column eluting with 0-10% MeOH (containing 10% 0.880 ammonia solution)/DCM. The isolated free base product was dissolved in DCM (5ml) and treated with excess 1 N HCI/diethyl ether solution (1 ml) and stirred for 10min. The mixture was evaporated (co-evaporated with acetone 2 x 10ml), triturated with acetone, then dried at 50 C under high vacuum for 16h to yield the title compound (E2) as a pale solid (0.055g). MS electrospray (+ion) 377 (MH+). 1 H NMR 8 (DMSO-d6) : 10.57 (1H, s), 9.07 (2H, d, J=6.4Hz), 7.88 (4H, m), 7.60 (2H, d, J= 7.6Hz), 4.15 (1H, m), 3.82-3. 33 (6H, m), 3.02 (2H, m), 2.62 (3H, s), 2.41-1. 62 (8H, m) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
EXAMPLE 40A 4'-acetyl(1,1'-biphenyl)-4-carboxylic acid The desired product was prepared by substituting 1-(4-bromophenyl)ethanone for 2-bromo-5-chlorothiophene in Example 29A. MS (APCI(-)) m/e 239 (M-H)-. | ||
Example 40A 4'-acetyl(1,1'-biphenyl)-4-carboxylic acid The desired product was prepared by substituting 1-(4-bromophenyl)ethanone for 2-bromo-5-chlorothiophene in Example 29A. MS (APCI(-)) m/e 239 (M-H)-. |
[ 178313-44-5 ]
4'-Acetyl-2'-methyl-[1,1'-biphenyl]-4-carboxylic acid
Similarity: 0.94
[ 1049130-93-9 ]
4'-Ethyl-[1,1'-biphenyl]-3-carboxylic acid
Similarity: 0.94
[ 1215206-74-8 ]
3'-Ethylbiphenyl-3-carboxylic acid
Similarity: 0.94
[ 178313-44-5 ]
4'-Acetyl-2'-methyl-[1,1'-biphenyl]-4-carboxylic acid
Similarity: 0.94
[ 408367-33-9 ]
3'-Acetyl-[1,1'-biphenyl]-2-carboxylic acid
Similarity: 0.89
[ 870245-77-5 ]
2'-Acetyl-[1,1'-biphenyl]-3-carboxylic acid
Similarity: 0.89
[ 178313-44-5 ]
4'-Acetyl-2'-methyl-[1,1'-biphenyl]-4-carboxylic acid
Similarity: 0.94
[ 1049130-93-9 ]
4'-Ethyl-[1,1'-biphenyl]-3-carboxylic acid
Similarity: 0.94
[ 1215206-74-8 ]
3'-Ethylbiphenyl-3-carboxylic acid
Similarity: 0.94